The introduction of ORLADEYO has been a runaway success, and this is likely to continue with new payors and subscribers getting on board and international sales just around the corner.
With two pivotal trials for BCX9930 in preparation after a very successful P1 trial, the company has another potential blockbuster that can be useful in multiple diseases.
The company is well-financed and within a couple of years, it should generate the cash to finance more market introductions.
Investors have to keep in mind that before FDA approvals, nothing is given, but the shares contain tremendous option value on the possible success of further approvals.